The Russian Ministry of Health has registered a new domestic drug for the treatment of complicated chronic infections. The press service of the ministry reported this on April 5.
The full cycle drug “Fluorothiazinone” was developed and produced by the Research Center of Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health and meets the requirements of the EAEU. It is intended for the treatment of bacterial infections caused by antibiotic-resistant microorganisms.
The ministry noted that Fluorothiazinone is an innovative broad-spectrum antibacterial agent and has no analogues in the world among drugs of this class. Based on the results of the evaluation, the high efficiency of its use and a favorable safety profile were confirmed.
“Fluorothiazinone is an original Russian development and is a drug with a mechanism of action different from antibiotics, which suppresses virulence and promotes the eradication of bacteria,” explained the chief freelance specialist urologist of the Ministry of Health, head of the Department of Urology of the Russian University of Medicine, Academician of the Russian Academy of Sciences Dmitry Pushkar.
According to him, the drug needs active clinical use and evaluation of results, however, in a clinical study of urological patients, Fluorothiazinone has already shown high efficiency.
“Resistance to antimicrobial drugs is an inevitable biological phenomenon, and the task of medical workers is to reduce the rate of its emergence and spread,” recalled in this regard Roman Kozlov, rector of the Smolensk State Medical University, chief freelance specialist in clinical microbiology and antimicrobial resistance of the Russian Ministry of Health.
Earlier, on April 3, Russian Prime Minister Mikhail Mishustin announced that Russia is completing clinical trials of the world's first drug that can stop the development of previously incurable ankylosing spondylitis. In addition, in 2023, more than 500 Russian medicines were released onto the market.
Prior to this, on March 27, the Federal Medical and Biological Agency of Russia announced that it had received a permanent registration certificate for the drug against coronavirus “MIR 19”. According to FMBA specialists, preclinical and clinical studies of the drug have demonstrated its high effectiveness and safety.
#Russian #Ministry #Health #registered #drug #treatment #complicated #infections
